Literature DB >> 25446652

H2 and H3 relaxin inhibit high glucose-induced apoptosis in neonatal rat ventricular myocytes.

Xiaohui Zhang1, Xiao Ma2, Meng Zhao1, Bo Zhang1, Jinyu Chi1, Wenxiu Liu1, Wenjia Chen1, Yu Fu1, Yue Liu1, Xinhua Yin3.   

Abstract

High concentrations of glucose induce cardiomyocyte apoptosis, and contribute to diabetic cardiomyopathy. Relaxin-2 and relaxin-3 are two members of the relaxin peptide family that are cardioprotective. However, it remains unknown whether relaxin-2 or relaxin-3 can regulate apoptosis in high glucose treated-neonatal rat ventricular myocytes (NRVMs). In cultured NRVMs, 33 mmol/l high glucose (HG) increased apoptosis in a time-dependent manner. HG-increased the protein expression of cleaved caspase-8 and -9, two initiators of the extrinsic and intrinsic pathways of apoptosis, Caspase-3 was attenuated by human recombinant relaxin-2 (H2 relaxin) or relaxin-3 (H3 relaxin), indicating that H2 and H3 relaxin inhibited HG-induced apoptosis. Furthermore, endoplasmic reticulum stress (ERS) markers CHOP and caspase-12 were markedly increased in HG-treated NRVMs, leading to apoptosis; this effect was also effectively attenuated by H2 relaxin or H3 relaxin. Treatment of NRVMs with HG reduced autophagy which cannot be adjusted by H2 relaxin or H3 relaxin. In conclusion, HG-induced apoptosis in NRVMs was mediated, in part, by the activation of the extrinsic and intrinsic pathways of apoptosis and ERS, all inhibited by H2 relaxin or H3 relaxin.
Copyright © 2014 Elsevier B.V. and Société française de biochimie et biologie Moléculaire (SFBBM). All rights reserved.

Entities:  

Keywords:  Apoptosis; Endoplasmic reticulum stress; H2 relaxin; H3 relaxin; High glucose

Mesh:

Substances:

Year:  2014        PMID: 25446652     DOI: 10.1016/j.biochi.2014.11.004

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  13 in total

Review 1.  The actions of relaxin on the human cardiovascular system.

Authors:  Mohsin Sarwar; Xiao-Jun Du; Thomas B Dschietzig; Roger J Summers
Journal:  Br J Pharmacol       Date:  2016-07-11       Impact factor: 8.739

2.  Dexmedetomidine alleviates postoperative cognitive dysfunction by inhibiting neuron excitation in aged rats.

Authors:  Bo Xiong; Qiqing Shi; Hao Fang
Journal:  Am J Transl Res       Date:  2016-01-15       Impact factor: 4.060

3.  Transcriptional up-regulation of relaxin-3 by Nur77 attenuates β-adrenergic agonist-induced apoptosis in cardiomyocytes.

Authors:  Xiaohua You; Zhi-Fu Guo; Fang Cheng; Bing Yi; Fan Yang; Xinzhu Liu; Ni Zhu; Xianxian Zhao; Guijun Yan; Xin-Liang Ma; Jianxin Sun
Journal:  J Biol Chem       Date:  2018-07-13       Impact factor: 5.157

Review 4.  Anti-fibrotic actions of relaxin.

Authors:  C S Samuel; S G Royce; T D Hewitson; K M Denton; T E Cooney; R G Bennett
Journal:  Br J Pharmacol       Date:  2016-07-07       Impact factor: 8.739

5.  Relaxin activates AMPK-AKT signaling and increases glucose uptake by cultured cardiomyocytes.

Authors:  A Aragón-Herrera; S Feijóo-Bandín; D Rodríguez-Penas; E Roselló-Lletí; M Portolés; M Rivera; M Bigazzi; D Bani; O Gualillo; J R González-Juanatey; F Lago
Journal:  Endocrine       Date:  2018-02-06       Impact factor: 3.633

Review 6.  Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protection.

Authors:  Javier Díez; Luis M Ruilope
Journal:  Eur Heart J Cardiovasc Pharmacother       Date:  2015-11-26

7.  H3 relaxin inhibits the collagen synthesis via ROS- and P2X7R-mediated NLRP3 inflammasome activation in cardiac fibroblasts under high glucose.

Authors:  Xiaohui Zhang; Yu Fu; Hui Li; Li Shen; Qing Chang; Liya Pan; Siting Hong; Xinhua Yin
Journal:  J Cell Mol Med       Date:  2018-01-05       Impact factor: 5.310

8.  Relaxin ameliorates high glucose-induced cardiomyocyte hypertrophy and apoptosis via the Notch1 pathway.

Authors:  Xiao Wei; Yuan Yang; Yin-Jiu Jiang; Jian-Ming Lei; Jing-Wen Guo; Hua Xiao
Journal:  Exp Ther Med       Date:  2017-11-06       Impact factor: 2.447

Review 9.  Relaxin-2 in Cardiometabolic Diseases: Mechanisms of Action and Future Perspectives.

Authors:  Sandra Feijóo-Bandín; Alana Aragón-Herrera; Diego Rodríguez-Penas; Manuel Portolés; Esther Roselló-Lletí; Miguel Rivera; José R González-Juanatey; Francisca Lago
Journal:  Front Physiol       Date:  2017-08-18       Impact factor: 4.566

Review 10.  Relaxin as a Therapeutic Target for the Cardiovascular Complications of Diabetes.

Authors:  Hooi Hooi Ng; Chen Huei Leo; Laura J Parry; Rebecca H Ritchie
Journal:  Front Pharmacol       Date:  2018-05-15       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.